Pediatric Vitiligo: Therapy, Safety, and Phototherapy Protocols
Key Takeaways First-line on face/neck: calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) as steroid-sparing agents. Backbone for generalized disease: NB-UVB […]
pimecrolimus 1%
Pimecrolimus 1% vs Placebo for Facial Vitiligo: Randomized Controlled Trial Overview
Key Takeaways Pimecrolimus 1% cream showed superiority to vehicle on facial endpoints (F-VASI) over ~12–24 weeks in split-face and parallel-arm
Pimecrolimus 1% vs Placebo for Facial Vitiligo: Randomized Controlled Trial Overview
Key Takeaways For facial vitiligo, pimecrolimus 1% shows superiority over placebo on F-VASI and global assessments in several RCTs/split-face designs.